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ABSTRACT
Objectives To determine whether observational studies
that use an electronic medical record database can
provide valid results of therapeutic effectiveness and to
develop new methods to enhance validity.
Design Data from the UK general practice research
database (GPRD) were used to replicate previously
performedrandomisedcontrolledtrials,totheextentthat
was feasible aside from randomisation.
Studies Six published randomised controlled trials.
Main outcome measure Cardiovascular outcomes
analysed by hazard ratios calculated with standard
biostatistical methods and a new analytical technique,
prior event rate ratio (PERR) adjustment.
ResultsInnineof17outcomecomparisons,therewereno
significant differences between results of randomised
controlled trials and database studies analysed using
standardbiostatisticalmethodsorPERRanalysis.Ineight
comparisons, Cox adjusted hazard ratios in the database
differed significantly from the results of the randomised
controlledtrials,suggestingunmeasuredconfounding. In
sevenoftheseeight,PERRadjustedhazardratiosdiffered
significantly from Cox adjusted hazard ratios, whereas in
five they didn’t differ significantly,and in three were more
similartothehazardratiofromtherandomisedcontrolled
trial,yieldingPERRresultsmoresimilartotherandomised
controlled trial than Cox (P<0.05).
Conclusions Although observational studies using
databases are subject to unmeasured confounding, our
new analytical technique (PERR), applied here to
cardiovascular outcomes, worked well to identify and
reduce the effects of such confounding. These results
suggest that electronic medical record databases can be
useful to investigate therapeutic effectiveness.
INTRODUCTION
The future widespread implementation of electronic
records in clinical practice will provide an enormous
opportunityforresearchrelatedtomedicaltreatments,
providedthisinformationiscompiledintorobust,well
designed databases and analysed with appropriate
methods. By contrast, incorrect analyses could have
important negative effects on medical treatment and
healthpolicy.Therefore,beforeimplementationofthis
approach for assessing effectiveness of treatment, we
need to assess the validity of the results from studies
using such databases and of the study design and
analytical strategies that are most likely to yield valid
results. The need for further investigation into these
strategies is widely supported.
1-7
Two major potential problems could arise in the use
of medical record databases to provide reliable
information concerning treatment outcomes: the
quality of the data contained within the database and
the ability of analyses of observational—that is, non-
experimental—data to provide valid results.
Considerable controversy exists over whether
observational studies can provide reliable information
on effectiveness of therapeutics.
128-15 Because of their
ability to balance measured and unmeasured con-
founders, randomised controlled trials remain the
highest level of evidence, whereas the quality of
evidence from observational studies is lower because
of confounding by indication and other biases related
to the effects of unmeasured covariates. Several
comparative analyses suggest that observational stu-
diesoftenyieldresultsreasonablyconsistentwiththose
ofrandomisedcontrolledtrials.Nevertheless,thereare
several well documented examples where the results
from observational studies were misleading.
1-3781617
Hormone treatment to protect against coronary artery
disease in postmenopausal women is one highly cited
example.
7-20Someauthoritiesbelievethattheresultsof
observational studies should be an important compo-
nent of evidence based medicine; some suggest their
reliability is limited to conditions where confounding
by indication is unlikely, as, for example, in studies of
unanticipatedadverseeffectsofdrugs,
21whereasothers
are sceptical of their value.
127-15
An important limitation applicable to previous
comparative analyses is that most of the observational
studies did not have rigorous inclusion and exclusion
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to the randomised controlled trials so that lack of
randomisation was not the only important
difference.
12152223
To overcome these limitations in validating an
observational study, we tested the value of a compre-
hensive longitudinal electronic clinical database, the
UK General Practice Research Database (GPRD),
using studies designed to replicate the design of
previously performed randomised controlled trials to
theextentthatwasfeasibleasidefromrandomisation.
24
Validityofthemethodwasmeasuredbycomparingthe
outcomes of the replicated GPRD study with those of
the randomised controlled trial.
25-29 The GPRD study
resultsdependedonboththequalityoftheinformation
in the database and whether observational data can
reproduce results from a randomised controlled trial.
We examined both the potential research value of
theelectronicmedicalrecorddatabaseandthevalidity
ofobservationalstudies.Wealsousedanewanalytical
method, prior event rate ratio (PERR) adjustment, to
enhance the validity of the results.
METHODS
GPRD database
The UK GPRD database contains information from
the electronic medical records of primary care
practices encompassing a representative sample of
about 5.7% of the UK population during 1990-2000
and contains records of over eight million patients.
2425
It includes the complete primary care medical record,
comprehensive information on essentially all medica-
tions prescribed, and information from outside con-
sultants and admissions to hospital. The box details
limitations and advantages of the database.
GPRD study protocol
Table 1 summarises database replications of six
randomisedcontrolledtrialsthathavebeenperformed
and reported in detail elsewhere.
2030-34 As far as
possible the database studies used the same inclusion
andexclusioncriteria,asimilarstudytimeframe,anda
similartreatmentregimenastherandomisedtrials.
25-29
Thus the major primary difference was the lack of
randomisationinthedatabasestudies,albeitthatother
issues such as use of placebo, nature of healthcare
delivery, and some characteristics of subjects entered
into randomisedtrialscomparedwiththose existingin
the general population can differ between a rando-
mised trial and a database study.
Selectionofthesubjectsforinclusioninthedatabase
studiesfollowedthe outlineshowninfigure1.Firstthe
exposedcohortwasselectedfromalldatabasesubjects
who met the inclusion criteria and received treatment
with the study treatment during a predefined recruit-
ment interval. The exposed cohort was finalised after
elimination of patients with exclusion criteria. Their
start time was the day of the first prescription of the
study drug. The unexposed cohort was selected from
all patients who met the inclusion criteria but did not
receive the study drug during the recruitment interval.
They were then age and sex matched to the exposed
patients with a computerised random selection pro-
gram, and their start time was considered identical to
thatofthe matchedexposedpatients.Then,thosewho
had exclusion criteria were eliminated.
The selection process differed for the database
matched to the Syst-Eur study because study entry
and start time for both the exposed and unexposed
cohorts was determined by measured blood pressure
that indicated systolic hypertension.
25
Alldatabasestudiesendedonapredefineddateoron
outcome stop points defined in the randomised
controlled trial. Patients were considered lost to
follow-up if they left the practice or the practice was
eliminated from the database before the end date. We
analysed database studies using a simulated “intention
to treat” paradigm where subsequent treatment of the
exposed and unexposed patients did not modify study
end time and also an “as treated” analysis in which the
study ended for an exposed or unexposed patient who
deviated from their treatment protocol.
Statistical analysis
We determined Cox unadjusted and adjusted hazard
ratiosforalloutcomes.Theadjustedhazardratiosused
a predetermined set of potential confounders that
included key demographics, medications at baseline,
and identified medical conditions. We imputed miss-
ingvaluesforsystolicbloodpressure,bodymassindex,
and smoking
35 and created five separate datasets. The
final estimates combined the results from the five
datasets, as described previously.
2635-37
We also analysed results with a propensity score
approach, which used all demographics, drug use at
baseline, and identified medical conditions as
confounders.
252638-40 Propensity scores were estimated
using logistic regression with the outcome being the
indicator of treatment and the covariates being all
confounders considered. For those with no missing
data, all covariates were used; whereas for those with
missing data (for body mass index, systolic blood
pressure, or smoking), we used separate logistic
regressionmodels,whichexcludedthemissingcovari-
ates, to estimate propensity scores. Analysis stratified
by the propensity scores balances the treated and
1 or more exclusion criteria
Met entry criteria
Treatment with study drug during recruitment
  interval
Meet entry criteria
No treatment with study drug (or similar)
  during recruitment interval
Final exposed
cohort
1 or more exclusion criteria
Final unexposed cohort
Random 2:1 or 3:1 match
with final exposed cohort
Unexposed Exposed
Fig 1 | Selection process for participants in database studies
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ates used in estimating the propensity scores. We
determined outcome hazard ratios for each fifth of the
propensityscoreandcombinedthefivehazardratiosto
determine an overall hazard ratio using a Cox model
treating the fifths as strata with different baseline
hazards. The propensity score thereby accounts for
missing confounders in a different fashion from the
multiple imputation method used with the Cox
analysis. The matched database study for Syst-Eur,
ourfirststudy,wasanalysedonlywithpropensityscore
analysis.
25
We also used a prior event rate ratio (PERR)
approach to adjust the Cox hazard ratio, as described
recently.
2829 This analysis requires that neither the
exposed nor unexposed patients are treated with the
study drugbefore the start of the study. It assumes that
the hazard ratio of the exposed to unexposed for a
specific outcome before the start of the study reflects
thecombinedeffectofallconfounders(bothmeasured
and unmeasured) independent of any influence of
treatment.
To apply the PERR adjustment method, we divided
the unadjusted hazard ratio of exposed versus unex-
posed groups during the study by the unadjusted
hazardratioofexposedversusunexposed“before”the
study. Thus if p=prior events and s=study events, the
calculation is: PERR adjusted HR=HRs/HRp. We
obtained confidence intervals for the PERR adjusted
hazard ratio using a bootstrap technique.
28 Hazard
ratios are reported because of variable observation
times for patients both before and during the study;
though incidence rate ratios produced similar results.
InallstudieswecarriedoutthePERRanalysisusing
a subset of patients who did not take the study drug at
anytimebeforethestartofthestudy.Innoinstancedid
Cox adjusted hazard ratios for this subset differ
meaningfully from the results in the overall cohort.
The time interval used to assess previous events
encompassed1January1987tothepatient’sstarttime.
If a patient had no medical or treatment record before
that date, their time interval began on the earliest
subsequent date with a record. If they had no records
before the study start time, they were not used in this
analysis.Theaveragetimeofthepreviousperiodforall
the outcomes assessed averaged 3.52 years (range 2.8-
3.9years). Analysisofthe impactofthe durationofthe
previous time period using the empirical data in these
studies suggested that encompassing events from 3-4.
5 years before study start time did not meaningfully
influence the results of the PERR analysis.
We compared differences between the hazard ratio
from the randomised trial and the database using a
standard normal z test, where the z score was obtained
from the difference between the logarithm of the
hazard ratio divided by the standard error of that
difference.
25
RESULTS
We collated and analysed the collective results of six
database studies reported previously.
25-29
Comparability between replicated database study and
randomised controlled trial
The size of the unexposed group in the database study
was always larger than the placebo group of the
randomised controlled trials (table 1). The exposed
groupinthedatabasestudy,however,wassmallerthan
the treated cohort in half the randomised controlled
trials. Furthermore, the database was inadequate to
replicate several randomised controlled trials because
of an insufficient number of exposed patients.
Table 1 |Comparison of study characteristics in randomised controlled trials and general practice research database (GPRD)
Study
No of subjects Treatment protocol
Trials Database
Trials Database Treated Placebo Exposed Unexposed
Syst-Eur* 2398 2297 2815 13 956 Nitrendipine,enalaprilorhydrochlorothiazide.
Target: 20 mm Hg decrease SBP
Dihydropyridine calcium channel blocker, ACE
inhibitor, or thiazide diuretic. No target
WHI (Women’s Health Initiative):
Intact uterus† 8506 8902 13 658 37 730 Conjugated oestrogen 0.625 mg/day;
medroxyprogesterone 5.0 mg/day
Conjugated oestrogen 0.625 mg/day;
norgestrel 150 µg on days 17-28
Hysterectomy‡ 5310 5429 6890 11 572 Conjugated oestrogen 0.625 mg/day Conjugated oestrogen 0.625 mg/day
4S§ 2221 2223 1280 2871 Simvastatin 20 mg/day. Target: total
cholesterol 115-200 mg/dl
Anystatin(80%receivedsimvastatin).Notarget
HOPE¶ 4645 4652 2812 26 286 Ramipril 10 mg/day Any ACE I inhibitor with ramipril equivalent
>4 mg/day (average dose 6.8 mg/day)
EUROPA** 6110 6108 2668 12 705 Perindopril 8 mg/day (ramipril equivalent
10 mg/day)
Any ACE inhibitor with ramipril equivalent
>4 mg/day (average dose 6.5 mg/day)
ACE=angiotensin converting enzyme.
*Antihypertensive treatment of older patients with isolated systolic hypertension in Europe.
25 30
†Postmenopausal women treated with combined hormone replacement.
20 26 41
‡Postmenopausal women with previous hysterectomy treated solely with conjugated oestrogen.
27 31 41
§Scandinavian simvastatin survival study of hypercholesterolaemic subjects with coronary artery disease treated with simvastatin.
28 32
¶Heart outcomes prevention evaluation study of ramipril (angiotensin converting enzyme inhibitor), treatment of patients either with established or at high risk for coronary artery disease.
29
33
**European trial on reduction of cardiac events with perindopril (angiotensin converting enzyme inhibitor) in patients with stable coronary artery disease.
29 34
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studies and randomised trials, the database cohort
typically differed from the respective trials in their
baseline demographic characteristics, existing comor-
bidities, and use of cardiovascular drugs.
25-29
Thedatabasetreatmentprotocolpreciselyreplicated
the trial in only one study (WHI-hysterectomy (see
table 1).Theotherdatabasestudiesusedthesameclass
of drug, rather than specific drug used in the trial.
Furthermore, identical dosing regimens could not be
replicated. It is worth noting that the prescription
database in GPRD can actually track data on medica-
tion prescribing better than many randomised con-
trolled trials.
Finally in contrast with the randomised controlled
trials,whererandomisationresultedinsimilarbaseline
health profiles of the treated and placebo arms, all the
database studies except Syst-Eur exhibited differences
in the baseline characteristics of the exposed and
unexposed groups.
Comparison of outcomes in the database studies and
randomised controlled trials
We focused on randomised controlled trials with
primary cardiovascular outcomes because they could
be replicated reasonably without the need for labora-
tory data. We report on death, myocardial infarction,
stroke, and coronary revascularisation (coronary
artery bypass grafts or percutaneous transluminal
coronary angioplasty (CABG/PTCA) or both). These
cardiovascular outcomes should be the least
susceptible to misclassification errors. Other outcome
results are provided in the primary publications, and
the results for breast cancer, colon cancer, and hip
fracture were similar in both the “intact uterus” and
“hysterectomy”WHIrandomisedcontrolledtrialsand
their respective database studies.
25-29
Table 2 and figure 2 show cardiovascular outcomes
and statistical comparisons for the six database studies
and trials. We have shown simulated “intention to
treat”results,butresultsofthe“astreated”analysesdid
not differ meaningfully. Cox adjusted and prior event
rate ratio (PERR) adjusted hazard ratios (performed in
five studies) are also shown.
Propensity score analyses (table 3) did not differ
meaningfullyfromtheanalysiswithCoxadjustedhazard
ratios. A minor exception was the death outcomes in the
HOPE and EUROPA studies, where the propensity
score adjusted hazard ratios were slightly lower than the
Cox adjusted hazard ratios and slightly more similar to
the hazard ratios from the randomised controlled trial.
Results from the WHI randomised controlled trial
for the entire cohort and also subdivided by age were
reported.
203141 We compared the database studies to
the overall WHI randomised controlled trial and also
to the results restricted to women aged <70, an age
profile more comparable with the study cohorts in the
database.
Cardiovascular outcomes
In nine of 17 comparisons of cardiovascular outcomes
there was no significant difference between the Cox
-2.0 -0.4 0.4 1.2 -1.2 -0.8 0 0.8 -1.6 -1.2 -0.4 0.4 1.2 2.0 2.8 -0.8 0 0.8 1.6 2.4 -1.2 -0.4 0 0.4 0.8 1.2 -0.8
Myocardial infarction CABG/PTCA Stroke
Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
WHI-hysterectomy
WHI-intact uterus
EUROPA
HOPE
4S
SYST EUR
RCT
GPRD-Cox
GPRD-PERR
Fig 2 | Comparisons between hazard ratios from randomised controlled trials (RCT) and adjusted hazard ratios for respective database studies. Data plotteda s
natural logarithms, so 0 on x axis indicates no difference between exposed and unexposed cohort. Database adjusted hazard ratios shown with both Cox and prior
event rate ratio (PERR) adjustment analysis. Results are shown for myocardial infarction, stroke, and coronary revascularisation (CABG/PTCA). GPRD=general
practice research database
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ratiosfromtherandomisedcontrolledtrials(seetable 2,
whichcomparesthetrialhazardratio,thedatabaseCox
adjustedhazardratio,andthedatabase-PERRadjusted
hazard ratios). In none of these nine comparisons did
the PERR analysis differ significantly from either the
trial hazard ratios or the Cox adjusted hazard ratios.
In eight of the 17 comparisons, however, the Cox
adjusted hazard ratios differed significantly from the
trial hazard ratios, suggesting the presence of unmea-
suredconfounding.Insevenoftheseeightinstancesthe
PERR adjusted hazard ratios differed significantly
from the Cox adjusted hazard ratios, and either did
not differ significantly (five outcomes) or were more
similar (two outcomes) to the trial hazard ratio. In the
otheroutcomethePERRhazardratiowasmoresimilar
to the trialbut didnot differ significantly from the Cox
adjusted hazard ratio. A Wilcoxon signed rank test
showed that when the Cox adjusted hazard ratio
differed significantly from the trial hazard ratio (n=8),
the PERR adjusted hazard ratio was significantly
(P<0.05) more similar to the trial hazard ratio than
the Cox adjusted hazard ratio.
Asthe17outcomesanalysedcamefromsixstudies,it
is reasonable to question the analysis of each outcome
asanindependentdatapoint.Asshowninthe4Sstudy,
however,thetwooutcomes(myocardialinfarctionand
coronary revascularisation) clearly behaved indepen-
dently of one another. Unmeasured confounding
affected revascularisation but had no discernible effect
on myocardial infarction. As the PERR analysis is
outcomespecificandderivedentirelyinthatfashion,it
seems reasonable to analyse the data assuming that
each individual outcome is independent.
In the aggregate, when the outcome results from the
database studies analysed by conventional statistical
methods are confirmed or corrected by the PERR
method, they are largely comparable with the results
from the respective randomised controlled trials.
The large confidence intervals in the PERR analysis
of all the WHI outcomes, which limits the inter-
pretation of this data, were due to the small number of
previous events. Surprisingly, despite this limitation,
the PERR adjusted hazard ratio was significantly
higher than the Cox adjusted hazard ratio and not
different from the randomised controlled trial hazard
ratio for both the myocardial infarction and stroke
outcomes in the WHI-hysterectomy study, suggesting
the presence of unmeasured confounding. The like-
lihood that unmeasured confounding influenced these
two outcomes is consistent with the significant differ-
ence between the Cox adjusted hazard ratios and the
randomised controlled trial hazard ratios.
Death
We have shown only Cox adjusted hazard ratios for
death because PERR adjustment cannot be done. The
Coxandthepropensityscoreadjustedhazardratiosfor
deathresembledtherandomisedcontrolledtrialresults
in three studies; however, they were higher than the
trial in the Syst-Eur study and lower in both the WHI
studies. The WHI results on death should be inter-
pretedcautiouslybecauseinbothstudiesasubsetofthe
overallcohortthatwasnotmissinganydataonbaseline
body mass index, systolic blood pressure, or smoking
did not show a significant decrease in death, despite
resultscomparable withtheoverallcohortforallother
outcomes.
DISCUSSION
Despite its shortcomings, this careful, albeit not
exhaustive, comparison between randomised con-
trolled trials and observational studies using data
from an electronic primary care medical record
database reveals several important insights. From an
overall perspective, our results suggest that observa-
tional studies using databases might produce valid
results concerning the efficacy of cardiovascular drug
treatments.
Rigour of database studies
Our studies comparing performance of the database
and randomisedcontrolled trialswere performedin as
rigorous fashion as possible.
In addition to using similar inclusion and exclusion
criteriaandrelativelysimilartimeframes,weanalysed
studieswithbothasimulated“intentiontotreat”andan
“as treated” design. We analysed data with multiple
imputation plus Cox adjusted hazard ratios, and also
propensityscoreplusstratifiedCoxunadjustedhazard
ratios. The propensity score is useful to identify
heterogeneity and also incorporates missing data into
the analysis in a fashion different from the multiple
imputations used with the primary Cox method. We
used a subset of the overall cohort without “missing
data” on the key confounders (systolic blood pressure,
body mass index, and smoking) as a secondary
verification analysis to ensure that missing data did
not influence the results in the overall cohort. We
assessed use of non-study drugs to confirm that
cointervention during the study did not account for
the results. Computerised random matching and
thereby start time delineation for the unexposed
The GPRD database
Advantages
 Comprehensive national healthcare system
 Representative sample of entire population
 All care centralised in general practice record
 All medications prescribed by general practitioner, generated by computer
 Contains around eight million patients
Limitations
 Lacks direct link to laboratory data (laboratory data inadequate)
 Missing data on smoking, systolic blood pressure, body mass index (about 30%)
 Limited data on onset of menopause
 Limited data on admission to hospital
 Lacks direct link to death certificates (cause of death not reliable)
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 5 of 9group obviated the potential for unanticipated bias
related to start time in the unexposed group.
Overall study results
We analysed results of the outcomes for myocardial
infarction, stroke, coronary revascularisation, and
death for six comparative studies (table 2 and fig 2).
Weexaminedtheaggregatedatabasestudyresultswith
conventional biostatistical analyses (Cox adjusted
hazard ratios or propensity score analyses, or both)
and our newly described prior event rate ratio (PERR)
adjustment technique.
2829
When analysed with conventional biostatistical
analyses, the database outcome results (independent
of death) did not differ significantly from those in the
randomised controlled trial in nine of the 17 compar-
isons. In no instance did the PERR analysis differ
significantly from the randomised controlled trial,
when there was no difference between the conven-
tional analyses and the trial.
As shown in table 2 and figure 2, when the database
outcomes analysed with conventional biostatistical
techniques differed significantly from the trial, the
PERR analysis results were either not significantly
differentfromormuchmoresimilartothetrialresults.
Theinstanceswherethedatabaseresultsanalysedby
conventional biostatistical methods differed impor-
tantly from the results in the trial presumably reflect
unmeasuredconfoundingbyindicationinthedatabase
studies. Thus our findings support concerns that the
validityofobservationalstudiesmustalwaysbeviewed
with circumspection. The studies reported herein,
however,suggestthatthePERRtechniquecanidentify
(by differing from the results with standard statistical
methods) and largely correct for the effects of
unmeasured confounding, when it exists. The avail-
ability in the database of previous event rates, rather
than only prevalence data, permitted performance of
this analysis.
PERR analytical technique
The underlying hypothesis of the PERR analytical
technique is that a comparison between the event rate
for a specific outcome in a cohort’s exposed and
unexposed patients before entry into the study should
reflect the effect of all confounders on that specific
outcome independent of the effect of treatment. This
assumption holds only when neither the exposed nor
unexposed patients have been treated with the study
drug before the start of the study. If so, the ratio
between the previous events in the exposed and
Table 2 |Comparison of outcome hazard ratios in randomised controlled trials and general practice research database (GPRD)
Death Myocardial infarction Stroke CABG/PTCA
Syst-Eur
Trial 0.86 (0.67 to 1.09) 0.70 (0.44 to 1.09) 0.58 (0.40 to 0.83) —
GPRD-Cox 1.23 (1.00 to 1.50)* 0.74 (0.52 to 1.07) 0.68 (0.51 to 0.94) —
WHI-intact uterus
Trial 0.98 (0.82 to 1.15) 1.11 (0.84 to 1.47)† 1.41 (1.07 to 1.85) 1.01 (0.83 to 1.22)
GPRD-Cox 0.75 (0.65 to 0.86)* 0.95 (0.78 to 1.16) 1.23 (0.99 to 1.52) 1.15 (0.79 to 1.67)
GPRD-PERR — 1.40 (0.87 to 2.44) 2.63 (1.38 to 7.43) 0.57 (0.22 to 1.56)
GPRD-no missing‡ 0.91 (0.79 to 1.05) ———
WHI-hysterectomy
Trial 1.01 (0.88 to 1.22) 0.89 (0.70 to 1.12) 1.39 (1.10 to 1.77) 0.93 (0.78 to 1.10)
GPRD-Cox 0.68 (0.57 to 0.81)* 0.50 (0.38 to 0.67)* 0.95 (0.74 to 1.23)* 0.59 (0.36 to 0.95)
GPRD-PERR — 1.28 (0.69 to 2.56)§ 3.06 (1.39 to 10.31)§ 1.22 (0.67 to 2.42)
GPRD-no missing‡ 0.82 (0.66 to 1.02) ———
4S
Trial 0.70 (0.58 to 0.85) 0.67 (0.58 to 0.77) 0.64 (0.47 to 0.88) 0.63 (0.54 to 0.74)
GPRD-Cox 0.71 (0.53 to 0.96) 0.79 (0.61 to 1.02) 0.90 (0.63 to 1.30) 2.22 (1.80 to 2.75)*
GPRD-PERR — 0.69 (0.51 to 0.93) NA¶ 1.00 (0.75 to 1.33)*§
HOPE
Trial 0.84 (0.75 to 0.95) 0.79 (0.70 to 0.89) 0.68 (0.56 to .84) 0.82 (0.74 to 0.92)
GPRD-Cox 0.94 (0.85 to 1.03) 1.42 (1.23 to 1.61)* 1.16 (0.99 to 1.35)* 1.67 1.34 to 2.07)*
GPRD-PERR — 0.62 (0.53 to 0.74)*§ 0.94 (0.77 to 1.14)* 0.75 (0.56 to 1.01)§
EUROPA
Trial 0.89 (0.77 to 1.02) 0.76 (0.66 to 0.89) 0.96 (0.72 to 1.28) 0.96 (0.85 to 1.08)
GPRD-Cox 1.06 (0.95 to 1.19) 1.36 (1.16 to 1.58)* 1.04 (0.84 to 1.29) 2.20 (1.85 to 2.62)*
GPRD-PERR — 0.84 (0.69 to 1.01)§ 0.77 (0.55 to 1.07) 1.26 (.97 to 1.62)§
CABG/PTCA=coronary artery bypass grafts or percutaneous transluminal coronary angioplasty
*Significant difference (P<0.05) compared with trial.
†Trial values for myocardial infarction reflect WHI re-analysis by age, encompassing 50-70 years.
‡Subset not missing any data for BMI, systolic blood pressure, or smoking.
§Significant difference (P<0.05) compared with GPRD Cox adjusted hazard ratio.
¶PERR could not be done because stroke was study exclusion criteria.
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of all identified and unidentified confounders.
Therefore, when the unadjusted incidence rate ratio
or hazard ratio of that outcome during the study is
divided by the ratio for that outcome before the study,
thisadjustment shouldcorrect forthe aggregate effects
of all identified and unmeasured confounders.
When there are no unmeasured confounders,
reflectedbysimilarresultsofthedatabaseCoxadjusted
hazardratioandtherandomisedcontrolledtrialhazard
ratio,thePERRadjustedresultsshouldbesimilartothe
Cox adjusted hazard ratio. Based on the empirical
findingsinthesestudies,thePERRadjustmentseemed
to function in this fashion.
When there are unmeasured confounders, presum-
ably resulting from confounding by indication, the
results of the PERR adjusted hazard ratio and the Cox
adjusted hazard ratio should differ. Our empirical
results show that in every instance where the compar-
ison of the Cox adjusted hazard ratio in the database
study differed from the results of the trial, suggesting
thepresenceof“unidentifiedconfounding,”thePERR
adjustmentyieldedaresultmuchmoreconsistentwith
the findings in the trial. Of most importance in all but
one instance where unmeasured confounding seemed
to be present, the PERR adjusted value identified the
presence of unmeasured confounding by differing
significantly from the Cox adjusted hazard ratio.
Identification of the PERR method emerged from
these studies because the direct comparison of the
database observational study and the randomised
controlled trial provided a presumed correct answer
against which to validate the database results. Further
investigation is necessary to fully validate the PERR
technique.Moreextensivestatisticalsimulationstudies
would determine its limitations and applications and
theapplicabilityofthemethodtoadditionaloutcomes.
It is also important to appreciate that this technique is
outcome specific; it cannot be extrapolated from one
outcometoanother.Finally,itisrestrictedtooutcomes
for which previous events can be ascertained. If an
outcome was a study exclusion criterion, it cannot be
analysed with this approach, nor can it be applied to
death.
The PERR method differs and seems to be more
widely applicable than other methods that have been
developed in an attempt to address hidden bias.
42 As
confirmed in our studies, propensity score analysis
does not overcome unmeasured confounding. When
combined with sensitivity analyses, however, it might
provide results that can be interpreted as unlikely to
have been influenced by unmeasured covariates.
43-45
Recently, propensity scores combined with regression
calibration were used to address unobserved variables
under certain conditions.
4647
Instrumental variable analysis, used commonly in
economics, has also been used to address unmeasured
confounding. An instrumental variable analysis
requires identification of a factor that affects the
assignment to treatment but has no direct effect on the
outcome.
48-50Itsapplicabilityandvalidityforstudiesof
therapeutic efficacy have not been widely
examined.
425152 Some have suggested that this techni-
queismostsuitedtoaddresshealthpolicyissuesrather
thanspecificclinicalissuesoftreatmenteffectiveness.
48
Both the propensity score calibration and the
instrumentalvariableanalysismethodshaveimportant
constraints.Thepropensityscorecalibrationtechnique
requiresthepresenceofavalidationstudy,whereasthe
instrumentalvariableanalysisrequiresidentificationof
an appropriate instrument. These requirements limit
their applicability to a wide variety of studies.
Of interest, the DID (difference-in-differences)
methodusedineconomicstudies,hassomesimilarities
tothePERRmethodinthatitcomparesthedifferences
betweenthedifferenceinbeforeandafterbehaviourin
two groups.
53-55 The key assumption behind the DID
method,similarto PERR, isthat the distribution ofthe
Table 3 |Hazard ratios adjusted for Cox analysis and propensity scores in general practice research database (GPRD)
Death Myocardial infarction Stroke CABG/PTCA
WHI-intact uterus
Cox 0.75 (0.65 to 0.86) 0.95 (0.78 to 1.16) 1.23 (0.99 to 1.52) 1.15 (0.79 to 1.67)
Propensity score 0.78 (0.69 to 0.89) 0.97 (0.80 to 1.17) 1.16 (0.95 to 1.42) 1.17 (0.82 to 1.70
WHI-hysterectomy
Cox 0.68 (0.57 to 0.81) 0.50 (0.38 to 0.67) 0.95 (0.74 to 1.23) 0.59 (0.36 to 0.95)
Propensity score 0.67 (0.57 to 0.80) 0.48 (0.36 to 0.64) 0.93 (0.72 to 1.19) 0.59 (0.37 to 0.96)
4S
Cox 0.71 (0.53 to 0.96) 0.79 (0.61 to 1.02) 0.90 (0.63 to 1.30) 2.22 (1.80 to 2.75)
Propensity score 0.65 (0.48 to 0.89) 0.76 (0.59 to 1.00) 0.87 (0.60 to 1.27) 1.93 (1.55 to 2.40)
HOPE
Cox 0.94 (0.85 to 1.03) 1.42 (1.23 to 1.61) 1.16 (0.99 to 1.35) 1.67 1.34 to 2.07)
Propensity score 0.79 (0.72 to 0.88)* 1.36 (1.17 to 1.58) 1.04 (0.89 to 1.23) 1.55 (1.24 to 1.94)
EUROPA
Cox 1.06 (0.95 to 1.19) 1.36 (1.16 to 1.58) 1.04 (0.84 to 1.29) 2.20 (1.85 to 2.62)
Propensity score 0.84 (0.75 to 0.95)* 1.31 (1.12 to 1.53) 0.86 (0.69 to 1.08) 2.37 (1.98 to 2.85)
CABG/PTCA=coronary artery bypass grafts or percutaneous transluminal coronary angioplasty
*Significant difference (P<0.05) compared with Cox adjusted hazard ratio.
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and the comparison group and the effect of these
unobserved confounding variables on the outcome
remains the same before and during the study period.
The DID method is also used commonly in psychol-
ogy, where it is called the before and after design with
an untreated comparison group.
5657
Deathwassignificantlyhigherinoneofourdatabase
studies (Syst-Eur) and it seemed to be significantly
lower in both of the database comparisons with the
WHI randomised controlled trial; however, for the
reasons enumerated these latter results should be
interpreted cautiously.
Future perspective and study limitations
Thus it seems from our studies that an electronic
medical record database can be an important tool for
ascertaining evidence based decisions with regard to
treatment. To maximise the value of future databases
they should be designed with all the advantages
enumerated for GPRD and also should overcome its
limitations(seebox).Ideallyfuturedatabasesshouldbe
much larger than GPRD, which includes about eight
million patients. On the basis of our work to date, we
estimate that 40-50 million patients are needed for the
breadth of future studies we can envisage.
Studies using such databases would not replace the
needtodorandomisedcontrolledtrialsbutcouldserve
asanimportanttooltosupplementthecontributionsof
trialstoevidencebasedmedicine.Oneexampleamong
many is to generalise the results of randomised
controlled trials. Although we have not comprehen-
sively examined this issue, our studies have shown the
feasibilityoffurthergeneralisingtheresultsoftheSyst-
Eur and WHI randomised controlled trials.
255859
AswellastheneedforfurthervalidationofthePERR
technique, several other limitations apply to this
investigative effort. The PERR technique should be
viewed currently as applicable only to analysis of a
study using a design similar to ours, which includes
similarinclusionandexclusioncriteriafortheexposed
and unexposed and a defined study start, recruitment
interval, and end time. Furthermore, the random
matching technique might be critical to assure that
bias does not exist in the start time for unexposed
patients. Application of the PERR technique to other
study designs will require its validation under those
conditions.
Another potential shortcoming of our studies is the
inability to exactly replicate all aspects of the rando-
mised controlled trial independent of randomisation,
such as exact dose of study drug, the role of placebos,
the possibilities of differences in health care, and other
differences between participants entered in rando-
mised controlled trials and those in the general
population. In addition, there is also the possibility of
inaccuracyofinformationinthedatabase(forinstance,
misclassification of outcome, ascertainment bias, etc).
The reasonably similar results of the database studies
and comparative randomised controlled trials, how-
ever, suggest these were not major problems.
Our current view is that the PERR analysis should
not be performed in isolation. We would recommend
its use along with conventional biostatistical analyses.
WhentheconventionalandPERRanalysesaresimilar,
“unmeasured confounding” would seem unlikely;
whereas when they differ “unmeasured confounding”
would seem likely. When unmeasured confounding
seemstobepresent,thePERRanalysisseemstoyielda
morevalidresult,butadditionalevaluationisrequired
to ascertain the veracity of this suggestion.
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